ABBVIE LTD
Get an alert when ABBVIE LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-04-06 (in 11mo)
Last made up 2026-03-23
Watchouts
None on the register
Cash
£180K
-84.4% vs 2023
Net assets
£704M
+3.6% vs 2023
Employees
1,152
+2.7% vs 2023
Profit before tax
£32M
+31.4% vs 2023
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £285,708,000 | £382,543,000 | |
| Operating profit | £25,592,000 | £33,595,000 | |
| Profit before tax | £24,213,000 | £31,807,000 | |
| Net profit | £18,671,000 | £28,392,000 | |
| Cash | £1,151,000 | £180,000 | |
| Total assets less current liabilities | £627,573,000 | £650,031,000 | |
| Net assets | £679,694,000 | £704,225,000 | |
| Equity | £679,694,000 | £704,225,000 | |
| Average employees | 1,122 | 1,152 | |
| Wages | £117,852,000 | £123,870,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 9.0% | 8.8% | |
| Net margin | 6.5% | 7.4% | |
| Return on capital employed | 4.1% | 5.2% | |
| Current ratio | 1.15x | 1.27x | |
| Interest cover | 4.21x | 5.83x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“As the Company is part of the AbbVie Inc. group cash pool, the directors have received written confirmation from AbbVie Inc. (the "Group") that they will make funds available to the Company if required to enable it to meet its liabilities as they fall due for a period of 12 months from the approval of the financial statements.”
Group structure
- ABBVIE LTD · parent
- AbbVie Australasia Holdings Limited 100%
- Allergan Limited 100%
- Allergan Holdings Limited 100%
- AbbVie Pty Limited 100%
- Allergan Australia Pty Limited 100%
Significant events
- “August 2024: SKYRIZI® (Risankizumab), an interleukin-23 (IL-23) for the treatment of ulcerative colitis (UC) was approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on August 21, 2024.”
- “November 2024: SKYRIZI® (Risankizumab), an interleukin-23 (IL-23) for the treatment of Crohn's Disease (CD) was approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on November 21, 2024.”
- “March 2024: Tepkinly® (epcoritamab) recommended as monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of therapy.”
- “August 2024: acquisition of Cerevel Therapeutics completed. The purchase includes a pipeline of clinical-stage and pre-clinical assets in diseases including schizophrenia, Parkinson's disease, and mood disorders.”
- “On 28 February 2025, the Allergan defined benefit Scheme was closed. All assets and liabilities were transferred into the AbbVie defined benefit scheme.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
5 active · 11 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MAHER, Niall Francis | Secretary | 2022-06-10 | — | — |
| BUTLER, Alice Elizabeth | Director | 2019-09-01 | Apr 1971 | British |
| GHAVAMI, Djamshid | Director | 2022-04-01 | Dec 1980 | Swedish |
| HOPKINSON, Stephen Mark | Director | 2024-08-01 | May 1978 | British |
| REENTS, Scott | Director | 2022-10-24 | Jun 1967 | American |
Show 11 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| POOTS, Kyle Alexander | Secretary | 2012-03-23 | 2022-06-10 |
| BOUYER, Jérôme Stéphane | Director | 2017-07-01 | 2019-09-01 |
| CHASE, William Joseph | Director | 2013-01-01 | 2019-04-01 |
| FREYMAN, Thomas Craig | Director | 2012-03-23 | 2013-01-01 |
| HUDSON, Susan Michelle | Director | 2012-03-23 | 2013-01-01 |
| MANNING, Todd David | Director | 2019-09-01 | 2024-07-31 |
| MICHAEL, Robert Andrew | Director | 2019-04-01 | 2022-10-24 |
| REGAN, Matt Joseph | Director | 2013-01-01 | 2017-05-31 |
| SMITH, Michael James | Director | 2012-03-23 | 2013-01-01 |
| SOENDERBY, Camilla Maria Kruchov | Director | 2012-03-23 | 2013-01-01 |
| WHITE, Gwenan Mair | Director | 2013-01-01 | 2019-09-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Abbvie Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 88 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-01-06 | CH01 | officers | Change person director company with change date | |
| 2025-09-24 | AA | accounts | Accounts with accounts type full | |
| 2025-04-01 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-03-26 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2024-10-25 | CH01 | officers | Change person director company with change date | |
| 2024-10-10 | AA | accounts | Accounts with accounts type full | |
| 2024-08-24 | TM01 | officers | Termination director company with name termination date | |
| 2024-08-22 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-04 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-10 | AA | accounts | Accounts with accounts type full | |
| 2023-03-23 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-10-24 | TM01 | officers | Termination director company with name termination date | |
| 2022-10-24 | AP01 | officers | Appoint person director company with name date | |
| 2022-10-10 | AA | accounts | Accounts with accounts type full | |
| 2022-06-10 | AP03 | officers | Appoint person secretary company with name date | |
| 2022-06-10 | TM02 | officers | Termination secretary company with name termination date | |
| 2022-04-01 | AP01 | officers | Appoint person director company with name date | |
| 2022-03-30 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-01-10 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+33.9%
£285,708,000 £382,543,000
-
Cash
-84.4%
£1,151,000 £180,000
-
Net assets
+3.6%
£679,694,000 £704,225,000
-
Employees
+2.7%
1,122 1,152
-
Operating profit
+31.3%
£25,592,000 £33,595,000
-
Profit before tax
+31.4%
£24,213,000 £31,807,000
-
Wages
+5.1%
£117,852,000 £123,870,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers